|1.||Olney, Nicholas: 1 article (04/2010)|
|2.||Rosen, Howard: 1 article (04/2010)|
04/01/2010 - "A subsequent phase III clinical trial assessing a lower dose of AVP-923 (20 or 30 mg DM/10 mg Q) for the treatment of PBA in patients with ALS or multiple sclerosis was implemented by AVANIR and demonstrated a favorable safety profile of AVP-923 while maintaining efficacy. "
01/01/2005 - "Medison Pharma (Israel) has obtained development, marketing and distribution rights to the dextromethorphan/quinidine combination for the treatment of emotional lability in patients with multiple sclerosis in Israel. "
|2.||Peripheral Nervous System Diseases (PNS Diseases)
|3.||Neuralgia (Stump Neuralgia)
04/01/2010 - "AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain."
04/01/2010 - "AVANIR Pharmaceuticals Inc, under license from Irisys Research & Development, is developing AVP-923 (Zenvia, Neurodex) for the treatment of pseudobulbar affect (PBA; in collaboration with Medison Pharma Ltd) and neuropathic pain associated with diabetic peripheral neuropathy. "
|4.||Nervous System Diseases (Neurological Disorders)
|1.||dextromethorphan - quinidine combination